drugset / Trial / NCT03085225
Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.
NaSingle-groupOpen-labelTreatment
Summary
A phase Ib trial study of trabectedin when prescribed in combination with durvalumab in locally advanced/unresectable soft-tissue sarcoma and ovarian carcinomas.
Timeline
- Start
- 2017-05-05
- Primary completion
- 2020-11-19
- Completion
- 2022-01-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1120 mg | Intravenous |
| Subject | Trabectedin | Small molecule | — | Intravenous |